Breaking News Instant updates and real-time market news.

EOLS

Evolus

$17.91

-0.25 (-1.38%)

07:08
08/12/19
08/12
07:08
08/12/19
07:08

Evolus expects European approval of Jeuveau in 2H19

The company said it "received a revised positive opinion from the Committee for Medicinal Products for Human Use and now expect European approval in the second half of 2019."

  • 12

    Aug

  • 15

    Aug

  • 04

    Sep

EOLS Evolus
$17.91

-0.25 (-1.38%)

06/28/19
WELS
06/28/19
INITIATION
Target $16
WELS
Market Perform
Wells Fargo starts Evolus with Market Perform rating, $16 price target
Wells Fargo analyst David Maris initiated coverage of Evolus with a Market Perform rating and $16 price target. The analyst notes Evolus is early in the launch of its lead product Jeuveau and that the costs to attain market share may be significant. Further, he believes the company may need additional financing.
07/11/19
WELS
07/11/19
NO CHANGE
Target $16
WELS
Market Perform
Evolus investors should keep eye on progressing Korean case, says Wells Fargo
A press report from Korea Biomedical Review indicates that the Seoul Central District Court has begun to test whether Nabota, the botulinum toxin of Daewoong Pharmaceutical, forms spores in the natural environment as an attempt to help decide the litigation between South Korean toxin manufacturers, Medytox and Daewoong, Wells Fargo analyst David Maris tells investors in a research note. Medytox sued Daewoong in 2017 alleging that Daewoong stole its botulinum toxin strain to manufacture its own, and thereby licensed U.S. cosmetic rights out to Evolus (EOLS) with a stolen botulinum toxin strain, Maris adds, while noting the report also said the first ruling should come in Q4 of this year. After speaking with company, Maris says the development is not unexpected. He believes, however, that investors should be aware of the progress and status of the litigation. The analyst keeps a Market Perform rating on Evolus shares with a $16 price target.
07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
07/31/19
STFL
07/31/19
NO CHANGE
STFL
Buy
Physician survey bodes well for Evolus and Revance, says Stifel
Stifel analyst Annabel Samimy said her survey of 50+ physicians in late June lead her to now believe that new toxins could have penetrations that exceed her current market-share estimates. The survey bodes well for Evolus (EOLS) in the near-term and for both Evolus and Revance (RVNC) in the longer-term while also indicating that Allergan's (AGN) Botox franchise may be more vulnerable than previously thought, Samimy tells investors. She previously had Evolus' Jeuveau reaching a peak market share of 15% and Revance's DaxibotulinumtoxinA reaching 20% shares by 2027, but her new "base case" assumes that Jeuveau peaks at 20% share and Daxi peaks at 25%, noted Samimy, who took down her Botox market share forecast for 2027 to 50%. Samimy raised her price target on Evolus shares to $33 from $30 and keeps a $50 price target on Revance while maintaining Buy ratings on both stocks.

TODAY'S FREE FLY STORIES

16:30
08/20/19
08/20
16:30
08/20/19
16:30
Options
Preliminary option volume of 15.2M today »

Preliminary option volume…

SCSG

SouthCrest Financial Group

$0.00

(0.00%)

16:28
08/20/19
08/20
16:28
08/20/19
16:28
Hot Stocks
SouthCrest Financial Group announces $5M share repurchase pact »

SouthCrest Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BP

BP

$36.44

-0.42 (-1.14%)

16:25
08/20/19
08/20
16:25
08/20/19
16:25
Initiation
BP initiated  »

BP initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

ABBV

AbbVie

$66.38

-0.17 (-0.26%)

16:23
08/20/19
08/20
16:23
08/20/19
16:23
Hot Stocks
AbbVie VP Jeffrey Stewart buys over $1M in company shares »

AbbVie VP Jeffrey Stewart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

CREE

Cree

$58.19

-0.09 (-0.15%)

16:20
08/20/19
08/20
16:20
08/20/19
16:20
Hot Stocks
Breaking Hot Stocks news story on Cree »

Cree down 7.5% after Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CVX

Chevron

$116.16

-1.14 (-0.97%)

16:20
08/20/19
08/20
16:20
08/20/19
16:20
Initiation
Chevron initiated  »

BMO Capital starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
08/20/19
08/20
16:20
08/20/19
16:20
Options
Closing CBOE SPX and VIX Index summary for August 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LZB

La-Z-Boy

$30.55

-1.325 (-4.16%)

16:19
08/20/19
08/20
16:19
08/20/19
16:19
Hot Stocks
La-Z-Boy CEO says 'home furnishings environment remains somewhat challenging' »

CEO Darrow concluded,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 27

    Aug

LZB

La-Z-Boy

$30.55

-1.325 (-4.16%)

16:18
08/20/19
08/20
16:18
08/20/19
16:18
Hot Stocks
Breaking Hot Stocks news story on La-Z-Boy »

La-Z-Boy reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 27

    Aug

LZB

La-Z-Boy

$30.55

-1.325 (-4.16%)

16:18
08/20/19
08/20
16:18
08/20/19
16:18
Hot Stocks
La-Z-Boy reports Q1 SSS for company-owned Retail segment up 3.5% »

In Q1: Written same-store…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 27

    Aug

NRZ

New Residential

$14.14

-0.115 (-0.81%)

16:17
08/20/19
08/20
16:17
08/20/19
16:17
Hot Stocks
New Residential announces $200M share repurchase program »

New Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
08/20/19
08/20
16:17
08/20/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$84.71

0.57 (0.68%)

16:16
08/20/19
08/20
16:16
08/20/19
16:16
Hot Stocks
SolarEdge appoints Uri Bechor as COO »

SolarEdge Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LZB

La-Z-Boy

$30.55

-1.325 (-4.16%)

16:16
08/20/19
08/20
16:16
08/20/19
16:16
Earnings
La-Z-Boy reports Q1 adjusted EPS 42c, consensus 34c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 27

    Aug

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
08/20/19
08/20
16:16
08/20/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXS

Plexus

$57.04

-0.48 (-0.83%)

16:15
08/20/19
08/20
16:15
08/20/19
16:15
Hot Stocks
Plexus announces $50M share repurchase program »

Plexus announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$48.56

-0.38 (-0.78%)

16:15
08/20/19
08/20
16:15
08/20/19
16:15
Initiation
Total initiated  »

Total initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
08/20/19
08/20
16:15
08/20/19
16:15
General news
Breaking General news story  »

San Francisco Federal…

XOM

Exxon Mobil

$69.03

-0.42 (-0.60%)

16:14
08/20/19
08/20
16:14
08/20/19
16:14
Initiation
Exxon Mobil initiated  »

Exxon Mobil initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LL

Lumber Liquidators

$8.42

0.36 (4.47%)

16:13
08/20/19
08/20
16:13
08/20/19
16:13
Hot Stocks
Lumber Liquidators founder Sullivan discloses 5.96% stake »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$115.99

-1.31 (-1.12%)

16:12
08/20/19
08/20
16:12
08/20/19
16:12
Initiation
Chevron initiated  »

Chevron initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$55.71

-0.37 (-0.66%)

16:11
08/20/19
08/20
16:11
08/20/19
16:11
Initiation
Royal Dutch Shell initiated  »

Royal Dutch Shell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BP

BP

$36.45

-0.41 (-1.11%)

16:11
08/20/19
08/20
16:11
08/20/19
16:11
Initiation
BP initiated  »

BP initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

URBN

Urban Outfitters

$20.98

0.12 (0.58%)

16:09
08/20/19
08/20
16:09
08/20/19
16:09
Hot Stocks
Breaking Hot Stocks news story on Urban Outfitters »

Urban Outfitters down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 22

    Aug

  • 25

    Sep

SCSC

Scansource

$31.55

-0.24 (-0.75%)

16:09
08/20/19
08/20
16:09
08/20/19
16:09
Earnings
Scansource sees Q1 non-GAAP EPS 70c-75c, consensus 35c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.